|
|
|
| A Study on Biocompatibility and Modification of Anticoagulant Coated Aterial Filter |
1 Graduate School, Tianjin Medical University, Tianjin 300170, China
2 Department of Heart Center, The Third Central Hospital, Tianjin 300170, China
3 Key Laboratory of Artificial Cells, Tianjin 300170, China |
|
|
|
|
Abstract In order to develop novel aterial filter with excellent biocompatibility, we prepared dacron filter coated with low molecular weight heparin (LMWH) or partial oxidation sodium alginate (OSA). The functional groups of the surface coating were determined with infrared spectroscopy. The biocompatibility was evaluated including contact angle, protein adhesion, in vitro platelet adhesion, coagulation indices, in vitro thrombosis. The safty was assessed by the loss of coating material, flow/roating speed, inlet and transfilter pressure during analog circulation. There are similar changes in the infrared spectroscopy of coated material at the location of LMWH‘s or OSA’s absorption peak. After being coated, the contact angle, albumin and fibrinogen adhering to the surface of dacron filter were decreased (P<0.05). For the LMWH coating, contact angle (32.7±4.65)°, albumin and fibrinogen adhered (2.56±0.81,1.63±0.37) μg/cm2 were higher than that (25.2±4.02)°,(2.00±0.32,1.32±0.14)μg/cm2 of OSA coating. The anticoagulant activity was notably promoted by coating, and dacron coated with LMWH was better than OSA (P<0.05). There was about 10% coating material loss in the analog circulation. The inlet and trans.filter pressure of coating filters was slightly increased, and flow/rotate was decreased. In conclusion, chemical graft-modification can be applied to the dacron filter. The biocompatibility of the coated materials is significantly promoted, and the safty meet the clinical demand. LMWH coating material has better hemocompatibility, while OSA coating material have better histocompatibility. For the carrier ability and low cost, OSA coating would get more development space.
|
|
|
|
|
|
［1］Barbosa NF,Cardinelli DM,Ercole FF,et al.Determinants of neurological complications with the use of extracorporeal circulation (ECC) ［J］.Arq Bras Cardiol,2010,95(6):151-117.
［2］Yarham G, Mulholland J. Preclinical laboratory evaluation of the new ‘AF’ arterial line filter range ［J］.Perfusion,2010,25(4):267-276.
［3］Jameel S,Colah S, Klein A. Recent advances in cardiopulmonary bypass techniques ［J］.Contin Educ Anaesth Crit Care Pain,2010,10(1): 20-23.
［4］柏淑颖，朱德明，王伟. 涂层技术在体外循环装置中的应用及意义 ［J］.中国体外循环杂志,2009,7(02):124-128.
［5］王琴梅，张亦霞，李卓萍，等. 多醛基海藻酸钠交联剂的制备及性能 ［J］. 应用化学,2010,27(02):155-158.
［6］Larm O, Larsson R, Olsson P. A new nonthrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue［J］. Biomater Med Devices Artif Organs, 1983,11(2-3):161-173.
［7］Bexborn F, Engberg AE, Sandholm K, et al. Hirudin versus heparin for use in whole blood in vitro biocompatibility models ［J］.Biomed Mater Res A, 2009,89(4):951-959.
［8］Smith PK, Mallia AK, Hermanson GT, et al.Colorimetric method for the assay of heparin content in immobilized heparin preparations ［J］.Anal Biochem,1980,109(2):466-473.
［9］Masuko T, Minami A, Iwasaki N, et al.Carbohydrate analysis by a phenolsulfuric acid method in microplate forma ［J］. Anal Biochem,2005,339(1):69-72.
［10］Solberg G.Extracoporeal circulation effect of longterm (24hour) circulation on blood component ［D］. Virginia: Virginia State University,2010.
［11］Gunaydin S. Clinical significance of coated extracorporeal circuits: a review of novel technologies ［J］. Perfusion,2004,19(1):33-41.
［12］Hussaini BE, Treanor PR, Healey NA, et al. Evaluation of blood components exposed to coated arterial filters in extracorporeal circuits ［J］. Perfusion,2009,24(5):317-323.
［13］高宁国，程秀兰，杨敬，等. 肝素结构与功能的研究进展 ［J］. 生物工程进展,1999,19(05):4-13.
［14］Wan Yuqing, Qu Xue, Lu Jun, et al. Characterization of surface property of poly(lactidecoglycolide) after oxygen plasma treatment ［J］. Biomaterials, 2004,25(19):4777-4783.
［15］Zhu Aiping, Chen Tian. Blood compatibility of surfaceengineered poly(ethylene terephthalate) via ocarboxymethylchitosan ［J］.Colloids Surf B Biointerfaces,2006,50(2):120-125.
［16］Wendel HP, Ziemer G.Coatingtechniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation ［J］. Eur J Cardiothorac Surg, 1999,16(3):342-350.
|
|
|
|
